Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD)

NCT03467217 PHASE2 TERMINATED Results posted

A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).

Details

Lead sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase	PHASE2
Status	TERMINATED
Enrolment	83
Start date	Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• NAFLD - Nonalcoholic Fatty Liver Disease

Interventions

• Losartan potassium
• Placebo losartan capsule

Countries

United States